Meeting on the Mesa 2021 | Addressing key issues in manufacturing advanced therapies

Monica Shah, MD, IQVIA, Washington, D.C., discusses ongoing hurdles that need to be overcome in manufacturing cell and gene therapies. Companies must be able to mass-produce products to ensure clinical trials can be conducted and for commercial use. Dr Shah additionally emphasizes the need for careful planning to ensure a robust supply is maintained, especially when treating prevalent diseases as a large patient population can put pressure on current manufacturing capabilities. This interview took place at Meeting on the Mesa 2021.